Next Article in Journal
Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution
Next Article in Special Issue
Treatments for HBV: A Glimpse into the Future
Previous Article in Journal
The Protein Kinase Receptor Modulates the Innate Immune Response against Tacaribe Virus
Previous Article in Special Issue
Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?
Article

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis

1
Women’s College Research Institute, Women’s College Hospital, Toronto, ON M5S 1B2, Canada
2
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada
3
Department of Family and Community Medicine, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada
4
Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada
5
Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada
6
Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA
7
Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Pietro Andreone and Stefano Brillanti
Received: 9 April 2021 / Revised: 9 June 2021 / Accepted: 29 June 2021 / Published: 7 July 2021
(This article belongs to the Special Issue Viral Hepatitis Treatment)
The 2019 novel coronavirus (COVID-19) pandemic has placed a significant strain on hepatitis programs and interventions (screening, diagnosis, and treatment) at a critical moment in the context of hepatitis C virus (HCV) elimination. We sought to quantify changes in Direct Acting Antiviral (DAA) utilization among different countries during the pandemic. We conducted a cross-sectional time series analysis between 1 September 2018 and 31 August 2020, using the IQVIA MIDAS database, which contains DAA purchase data for 54 countries. We examined the percent change in DAA units dispensed (e.g., pills and capsules) from March to August 2019 to the same period of time in 2020 across the 54 countries. Interrupted time-series analysis was used to examine the impact of COVID-19 on monthly rates of DAA utilization across each of the major developed economies (G7 nations). Overall, 46 of 54 (85%) jurisdictions experienced a decline in DAA utilization during the pandemic, with an average of −43% (range: −1% in Finland to −93% in Brazil). All high HCV prevalence (HCV prevalence > 2%) countries in the database experienced a decline in utilization, average −49% (range: −17% in Kazakhstan to −90% in Egypt). Across the G7 nations, we also observed a decreased trend in DAA utilization during the early months of the pandemic, with significant declines (p < 0.01) for Canada, Germany, the United Kingdom, and the United States of America. The global response to COVID-19 led to a large decrease in DAA utilization globally. Deliberate efforts to counteract the impact of COVID-19 on treatment delivery are needed to support the goal of HCV elimination. View Full-Text
Keywords: antivirals; hepatitis C; COVID-19; drug policy; time series antivirals; hepatitis C; COVID-19; drug policy; time series
Show Figures

Figure 1

MDPI and ACS Style

Shakeri, A.; Konstantelos, N.; Chu, C.; Antoniou, T.; Feld, J.; Suda, K.J.; Tadrous, M. Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. Viruses 2021, 13, 1314. https://0-doi-org.brum.beds.ac.uk/10.3390/v13071314

AMA Style

Shakeri A, Konstantelos N, Chu C, Antoniou T, Feld J, Suda KJ, Tadrous M. Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. Viruses. 2021; 13(7):1314. https://0-doi-org.brum.beds.ac.uk/10.3390/v13071314

Chicago/Turabian Style

Shakeri, Ahmad, Natalia Konstantelos, Cherry Chu, Tony Antoniou, Jordan Feld, Katie J. Suda, and Mina Tadrous. 2021. "Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis" Viruses 13, no. 7: 1314. https://0-doi-org.brum.beds.ac.uk/10.3390/v13071314

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop